Ritholtz Wealth Management Has $3.50 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Ritholtz Wealth Management lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 13.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,143 shares of the medical research company’s stock after selling 1,826 shares during the period. Ritholtz Wealth Management’s holdings in Amgen were worth $3,497,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of AMGN. Fuller & Thaler Asset Management Inc. raised its stake in Amgen by 1.7% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after buying an additional 193 shares during the last quarter. Diversified Trust Co raised its stake in Amgen by 76.8% during the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock worth $10,857,000 after buying an additional 16,376 shares during the last quarter. Nicolet Advisory Services LLC increased its stake in Amgen by 4.4% in the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 117 shares in the last quarter. Platform Technology Partners increased its stake in Amgen by 7.4% in the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after purchasing an additional 402 shares in the last quarter. Finally, Busey Trust CO increased its stake in Amgen by 1.2% in the third quarter. Busey Trust CO now owns 76,703 shares of the medical research company’s stock valued at $20,615,000 after purchasing an additional 894 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.7 %

AMGN opened at $284.32 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The stock has a market cap of $152.37 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.66 and a beta of 0.58. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company’s 50-day moving average price is $290.09 and its two-hundred day moving average price is $280.70.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same quarter in the previous year, the firm posted $4.09 earnings per share. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, equities analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.17%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. The Goldman Sachs Group boosted their target price on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Leerink Partnrs downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Morgan Stanley decreased their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. BMO Capital Markets raised shares of Amgen from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $286.00 to $326.00 in a research report on Tuesday, December 19th. Finally, Daiwa Capital Markets raised shares of Amgen from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $264.00 to $320.00 in a research report on Thursday, December 21st. One analyst has rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus target price of $295.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.